	US 11,866,451 B2
	Salts and crystalline forms of a PD-1/PD-L1 inhibitor
Zhongjiang Jia, Kennett Square, PA (US); Shili Chen, Newark, DE (US); Yi Li, Newark, DE (US); Timothy Martin, Hockessin, DE (US); Bo Shen, Garnet Valley, PA (US); Naijing Su, Hockessin, DE (US); Jiacheng Zhou, Newark, DE (US); and Qun Li, Newark, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Nov. 10, 2020, as Appl. No. 17/094,396.
Claims priority of provisional application 63/022,131, filed on May 8, 2020.
Claims priority of provisional application 62/933,869, filed on Nov. 11, 2019.
Prior Publication US 2021/0139511 A1, May 13, 2021
Int. Cl. C07D 519/00 (2006.01); A61K 9/00 (2006.01); C07C 61/135 (2006.01); C07C 211/56 (2006.01)

CPC C07D 519/00 (2013.01) [A61K 9/0053 (2013.01); C07C 61/135 (2013.01); C07C 211/56 (2013.01); C07B 2200/13 (2013.01)]

33 Claims

1. A salt, which is 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) di-hydrochloric acid salt.